ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
ProPhase Labs, Inc. (Nasdaq: PRPH) has appointed Bill White as the new Chief Financial Officer, effective May 23, 2022. Mr. White brings over 30 years of experience, previously serving as CFO of Intellicheck, Inc. and co-founding FocusMicro, Inc., where he grew revenues to over $36 million in five years. He will replace Monica Brady, who will continue with the company in a different capacity. White has been awarded a stock option for 400,000 shares with an exercise price of $6.74 per share. This appointment is seen as a strategic move to enhance the company’s financial management and growth.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on May 13, 2022, at 11:00 a.m. ET to discuss first-quarter results for the period ending March 31, 2022. CEO Ted Karkus will lead the call, which will include a question-and-answer session. Participants can register via a provided link and will receive dial-in details upon registration. Toll-free dial-in is available at 1-866-777-2509 for U.S. callers, and international callers can use 1-412-317-5413. The conference call will be broadcast live and available for replay after it concludes.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1:30 PM EST. The presentation will be accessible through a webcast link provided in the announcement.
ProPhase Labs focuses on diagnostics and genomics, offering services like whole genome sequencing and COVID-19 testing through its CLIA-certified laboratories. The company aims to expand its testing capabilities globally and continues to pursue strategic investments.
ProPhase Labs (NASDAQ: PRPH) reported strong financial results for the year ending December 31, 2021, with net revenue of $79 million, marking a 445% increase from the previous year. The company achieved a net income of $6.3 million or $0.41 per share, compared to a net loss of $2.1 million in 2020. The fourth quarter showcased net revenues of $45.2 million and a net income of $10.6 million. Adjusted EBITDA for 2021 was $18.1 million. ProPhase's new diagnostic services significantly drove growth, while strategic acquisitions and improved operational efficiencies indicate a promising outlook for 2022.
ProPhase Labs (NASDAQ: PRPH) announced a conference call on March 30, 2022, at 11:00 a.m. ET, to discuss the results for its fourth quarter and full year ending December 31, 2021. This call will be hosted by CEO Ted Karkus and include a Q&A session. A press release with detailed results will precede the call. Participants can register online to receive dial-in information, or call in directly using provided toll-free numbers.
ProPhase Labs offers diagnostic, genomics testing, and contract manufacturing services, with subsidiaries focusing on a range of healthcare solutions.
ProPhase Labs, Inc. (NASDAQ: PRPH) has declared a special cash dividend of $0.30 per share, payable on March 10, 2022, to stockholders of record as of March 1, 2022. This decision follows strong projected financial performance for Q4 2021 and the upcoming Q1 2022, with significant growth in net income and EBITDA. Chairman Ted Karkus emphasized a commitment to returning capital to shareholders while maintaining ample liquidity for future growth opportunities.
ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference from February 8-11, 2022. His presentation is scheduled for February 9, 2022, at 12:00 PM ET.
Additionally, Karkus will be available for one-on-one investor meetings on February 10-11. ProPhase Labs focuses on biotech and genomics, providing testing services and genomics data for healthcare advancements.
ProPhase Labs (NASDAQ: PRPH) reports significant growth in PCR COVID-19 testing volumes, exceeding 300,000 tests in Q4 2021, a sharp increase from about 110,000 in Q1 2021. The rise is attributed to a growing customer base and the emergence of the Omicron variant. The company expanded its workforce, increasing lab personnel from 50 to over 250 to meet demand while maintaining average result turnaround times of under 48 hours. Looking ahead, ProPhase anticipates ongoing growth across its testing and genomic services throughout 2022.
ProPhase Labs (Nasdaq: PRPH) announces that CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand for registered attendees starting at 7:00 a.m. ET on January 10.
ProPhase Labs is a diversified biotech company focusing on genomics and CLIA lab services, including COVID-19 testing, whole genome sequencing, and genetic research.
ProPhase Labs (NASDAQ: PRPH) has appointed Sam A. Beeler as Chief Strategy Officer while promoting Alice Lioi and Jason Karkus to Executive Vice Presidents/Co-Chief Operating Officers, and Sergio Miralles to Executive Vice President/Chief Information Officer. CEO Ted Karkus highlighted Beeler's role in enhancing Nebula Genomics' presence in personalized medicine and securing lower Whole Genome Sequencing prices. The promotions recognize the leadership of Lioi, Karkus, and Miralles in developing ProPhase Diagnostics and expanding its lab services.